1. Home
  2. GSL vs KLRA Comparison

GSL vs KLRA Comparison

Compare GSL & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSL

Global Ship Lease Inc New

HOLD

Current Price

$41.89

Market Cap

1.5B

ML Signal

HOLD

Logo Kailera Therapeutics Inc. Common Stock

KLRA

Kailera Therapeutics Inc. Common Stock

HOLD

Current Price

$12.75

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSL
KLRA
Founded
2007
2024
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2008
2026

Fundamental Metrics

Financial Performance
Metric
GSL
KLRA
Price
$41.89
$12.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
★ $51.00
$42.40
AVG Volume (30 Days)
294.2K
★ 1.3M
Earning Date
11-09-2026
11-23-2026
Dividend Yield
★ 6.04%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.53
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.49
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.76
$9.76
52 Week High
$46.57
$23.82

Technical Indicators

Market Signals
Indicator
GSL
KLRA
Relative Strength Index (RSI) 39.89 52.61
Support Level $35.73 $9.76
Resistance Level $41.95 $19.15
Average True Range (ATR) 1.17 0.86
MACD -0.32 0.44
Stochastic Oscillator 27.03 82.09

Price Performance

Historical Comparison
GSL
KLRA

About GSL Global Ship Lease Inc New

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.

About KLRA Kailera Therapeutics Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Share on Social Networks: